Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250042 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00250042 is a Phase 2 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 6 participants.
The verdict
NCT00250042, a Phase 2 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
Interventions
- DRUG Gleevec and Arsenic Trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250042
The ClinicalTrials.gov registry entry for NCT00250042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gleevec and Arsenic Trioxide is the first listed.
NCT00250042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250042 about?
NCT00250042 is a clinical study titled "A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec". 1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
What is the current status of trial NCT00250042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2004-04. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00250042?
The interventions under investigation include: Gleevec and Arsenic Trioxide (DRUG).
Who is sponsoring clinical trial NCT00250042?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.